Collaboration and License Agreements - Additional Information (Detail) |
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2020
USD ($)
Agreement
|
Mar. 31, 2019
USD ($)
|
|
| Janssen Pharmaceutical NV [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Accrued royalties | $ 0 | $ 0 |
| Janssen Pharmaceutical NV [Member] | Maximum [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Percentage of royalty on net sales | 8.00% | |
| Janssen Pharmaceuticals, Inc. [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Number of development and license agreements | Agreement | 2 | |
| DiaTex, Inc. [Member] | ||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
| Royalty payment | $ 0 | 0 |
| Development payment | $ 0 | $ 0 |
| X | ||||||||||
- Definition Development payment. No definition available.
|
| X | ||||||||||
- Definition Number of development and license agreements. No definition available.
|
| X | ||||||||||
- Definition Royalty percentage based on net sales. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of cash paid for royalties during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|